188 related articles for article (PubMed ID: 8395511)
21. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
22. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
23. Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An
Farsani FM; Ganjalikhany MR; Vallian S
Curr Cancer Drug Targets; 2017; 17(7):657-668. PubMed ID: 27834128
[TBL] [Abstract][Full Text] [Related]
24. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
25. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Elsea SH; Hsiung Y; Nitiss JL; Osheroff N
J Biol Chem; 1995 Jan; 270(4):1913-20. PubMed ID: 7829529
[TBL] [Abstract][Full Text] [Related]
26. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
27. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
29. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Dong J; Kohn KW; Pommier Y
J Biol Chem; 1999 Oct; 274(40):28246-55. PubMed ID: 10497180
[TBL] [Abstract][Full Text] [Related]
31. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Oct; 92(10):1133-7. PubMed ID: 11676865
[TBL] [Abstract][Full Text] [Related]
32. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
33. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Rose A; Nicklaus MC; Pommier Y
J Biol Chem; 1999 Mar; 274(11):7292-301. PubMed ID: 10066792
[TBL] [Abstract][Full Text] [Related]
34. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
35. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
36. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
Lee MS; Wang JC; Beran M
J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
[TBL] [Abstract][Full Text] [Related]
37. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
[TBL] [Abstract][Full Text] [Related]
38. Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.
Rogojina AT; Nitiss JL
J Biol Chem; 2008 Oct; 283(43):29239-50. PubMed ID: 18723844
[TBL] [Abstract][Full Text] [Related]
39. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Benchokroun Y; Couprie J; Larsen AK
Biochem Pharmacol; 1995 Jan; 49(3):305-13. PubMed ID: 7857317
[TBL] [Abstract][Full Text] [Related]
40. Molecular cloning and genetic mapping of the DNA topoisomerase II gene of Saccharomyces cerevisiae.
Voelkel-Meiman K; DiNardo S; Sternglanz R
Gene; 1986; 42(2):193-9. PubMed ID: 3015732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
